Novartis Failure Raises Questions for Dyne’s 2027 DM1 Readout
Novartis’ DM1 trial miss hit Dyne. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy.
Already have an account? Sign in.